215 related articles for article (PubMed ID: 37455281)
1. Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation.
Tantisuwat L; Saengklub N; Boonpala P; Kumphune S; Panyasing Y; Kalandakanond-Thongsong S; Kijtawornrat A
Sci Rep; 2023 Jul; 13(1):11472. PubMed ID: 37455281
[TBL] [Abstract][Full Text] [Related]
2. Effect of Neprilysin Inhibition for Ischemic Mitral Regurgitation after Myocardial Injury.
Lee S; Hwang HS; Song N; Kang GH; Choi KH; Ji E; Song JM; Kang DH
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445301
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.
Pfau D; Thorn SL; Zhang J; Mikush N; Renaud JM; Klein R; deKemp RA; Wu X; Hu X; Sinusas AJ; Young LH; Tirziu D
Sci Rep; 2019 Apr; 9(1):5791. PubMed ID: 30962467
[TBL] [Abstract][Full Text] [Related]
4. Sacubitril/Valsartan Averts Adverse Post-Infarction Ventricular Remodeling and Preserves Systolic Function in Rabbits.
Torrado J; Cain C; Mauro AG; Romeo F; Ockaili R; Chau VQ; Nestler JA; Devarakonda T; Ghosh S; Das A; Salloum FN
J Am Coll Cardiol; 2018 Nov; 72(19):2342-2356. PubMed ID: 30384891
[TBL] [Abstract][Full Text] [Related]
5. Changes in mid-regional pro-adrenomedullin during treatment with sacubitril/valsartan.
Myhre PL; Liu Y; Kulac IJ; Claggett BL; Prescott MF; Felker GM; Butler J; Piña IL; Rouleau JL; Zile MR; McMurray JJV; Ward JH; Solomon SD; Januzzi JL
Eur J Heart Fail; 2023 Aug; 25(8):1396-1405. PubMed ID: 37401523
[TBL] [Abstract][Full Text] [Related]
6. Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.
Schauer A; Adams V; Augstein A; Jannasch A; Draskowski R; Kirchhoff V; Goto K; Mittag J; Galli R; Männel A; Barthel P; Linke A; Winzer EB
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808232
[TBL] [Abstract][Full Text] [Related]
7. Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats.
Li Q; Fang Y; Peng DW; Li LA; Deng CY; Yang H; Kuang SJ; Li QQ; Zhang MZ; Zeng P; Zhang QH; Liu Y; Deng H; Wei W; Xue YM; Wu SL; Rao F
Eur J Pharmacol; 2023 Aug; 952():175754. PubMed ID: 37182595
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.
Kang DH; Park SJ; Shin SH; Hong GR; Lee S; Kim MS; Yun SC; Song JM; Park SW; Kim JJ
Circulation; 2019 Mar; 139(11):1354-1365. PubMed ID: 30586756
[TBL] [Abstract][Full Text] [Related]
9. Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
Aroor AR; Mummidi S; Lopez-Alvarenga JC; Das N; Habibi J; Jia G; Lastra G; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2021 Apr; 20(1):80. PubMed ID: 33882908
[TBL] [Abstract][Full Text] [Related]
10. Synergy between sacubitril and valsartan leads to hemodynamic, antifibrotic, and exercise tolerance benefits in rats with preexisting heart failure.
Maslov MY; Foianini S; Mayer D; Orlov MV; Lovich MA
Am J Physiol Heart Circ Physiol; 2019 Feb; 316(2):H289-H297. PubMed ID: 30461302
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin Receptor-Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension.
Sharifi Kia D; Benza E; Bachman TN; Tushak C; Kim K; Simon MA
J Am Heart Assoc; 2020 Jul; 9(13):e015708. PubMed ID: 32552157
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts.
Li X; Braza J; Mende U; Choudhary G; Zhang P
Sci Rep; 2021 Aug; 11(1):16542. PubMed ID: 34400686
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
Clements RT; Vang A; Fernandez-Nicolas A; Kue NR; Mancini TJ; Morrison AR; Mallem K; McCullough DJ; Choudhary G
Circ Heart Fail; 2019 Nov; 12(11):e005819. PubMed ID: 31707802
[TBL] [Abstract][Full Text] [Related]
14. Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload.
Nordén ES; Bendiksen BA; Andresen H; Bergo KK; Espe EK; Hasic A; Hauge-Iversen IM; Veras I; Hussain RI; Sjaastad I; Christensen G; Cataliotti A
ESC Heart Fail; 2021 Apr; 8(2):918-927. PubMed ID: 33497525
[TBL] [Abstract][Full Text] [Related]
15. Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts.
Burke RM; Lighthouse JK; Mickelsen DM; Small EM
Circ Heart Fail; 2019 Apr; 12(4):e005565. PubMed ID: 30998392
[TBL] [Abstract][Full Text] [Related]
16. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in
Myakala K; Jones BA; Wang XX; Levi M
Am J Physiol Renal Physiol; 2021 Jun; 320(6):F1133-F1151. PubMed ID: 33870733
[TBL] [Abstract][Full Text] [Related]
17. Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?
Villani A; Ravaro S; Cerea P; Caravita S; Ciambellotti F; Branzi G; Munforti C; Parati G; Malfatto G
J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):682-687. PubMed ID: 32744827
[TBL] [Abstract][Full Text] [Related]
18. Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.
Li X; Zhu Q; Wang Q; Zhang Q; Zheng Y; Wang L; Jin Q
Cardiovasc Drugs Ther; 2020 Oct; 34(5):629-640. PubMed ID: 32444995
[TBL] [Abstract][Full Text] [Related]
19. Sacubitril/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction.
Shi YJ; Yang CG; Qiao WB; Liu YC; Liu SY; Dong GJ
Eur J Pharmacol; 2023 Dec; 961():176170. PubMed ID: 37939991
[TBL] [Abstract][Full Text] [Related]
20. The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat.
Habibi J; Aroor AR; Das NA; Manrique-Acevedo CM; Johnson MS; Hayden MR; Nistala R; Wiedmeyer C; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2019 Mar; 18(1):40. PubMed ID: 30909895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
